AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 28930852 — intervention group
Group type: EXPERIMENTAL
Intervention: semi-immersive virtual training with body shadows (S-IVTS group)
Number of subjects: 20
Study 28930852 — intervention group
Group type: COMPARATOR
Intervention: semi-immersive virtual training without body shadows (S-IVT group)
Number of subjects: 20
Study 28931244 — intervention group
Group type: EXPERIMENTAL
Intervention: Trivalent influenza vaccine (TIV)
Number of subjects: 884
Study 28931244 — intervention group
Group type: COMPARATOR
Intervention: Control group (non-vaccinated)
Number of subjects: 884
Study 28931437 — intervention group
Group type: EXPERIMENTAL
Intervention: MitraClip intervention
Number of subjects: 45
Study 28931498 — intervention group
Group type: EXPERIMENTAL
Intervention: Smartphone app (ColoprAPP)
Number of subjects: 25
Study 28931498 — intervention group
Group type: COMPARATOR
Intervention: Control group (regular colonoscopy preparation leaflet)
Number of subjects: 25
Study 28931501 — intervention group
Group type: EXPERIMENTAL
Intervention: Cascade screening for HBOC and LS
Number of subjects: 0
Study 28931501 — intervention group
Group type: EXPERIMENTAL
Intervention: Family-based communication, coping, and decision support intervention
Number of subjects: 0
Study 28931529 — intervention group
Group type: EXPERIMENTAL
Intervention: ECG strain (n=168, 2.6%)
Number of subjects: 6441
Study 28931529 — intervention group
Group type: EXPERIMENTAL
Intervention: ECG strain
Number of subjects: 6441
Study 28932269 — intervention group
Group type: EXPERIMENTAL
Intervention: IBS-D Daily Symptom Diary and Event Log
Number of subjects: 434
Study 28932270 — intervention group
Group type: EXPERIMENTAL
Intervention: Open-label rifaximin 550 mg three times daily for 2 weeks
Number of subjects: 2579
Study 28932270 — intervention group
Group type: EXPERIMENTAL
Intervention: Double-blind rifaximin (two 2-week courses)
Number of subjects: 2579
Study 28932270 — intervention group
Group type: COMPARATOR
Intervention: Placebo (two 2-week courses)
Number of subjects: 2579
Study 28932579 — intervention group
Group type: EXPERIMENTAL
Intervention: Video-assisted thoracoscopic surgery (VATS)
Number of subjects: 300
Study 28932579 — intervention group
Group type: EXPERIMENTAL
Intervention: Stereotactic ablative body radiotherapy (SABR)
Number of subjects: 300
Study 28932752 — intervention group
Group type: EXPERIMENTAL
Intervention: rhBMP-12/ACS
Number of subjects: 20
Study 28932752 — intervention group
Group type: COMPARATOR
Intervention: SOC control
Number of subjects: 20
Study 28932928 — intervention group
Group type: EXPERIMENTAL
Intervention: Single 4.1 mg oral solution dose of ixazomib
Number of subjects: 0
Study 28933971 — intervention group
Group type: EXPERIMENTAL
Intervention: Fp MDPI 200 mcg
Number of subjects: 40
Study 28933971 — intervention group
Group type: EXPERIMENTAL
Intervention: FS MDPI 200/12.5 mcg
Number of subjects: 40
Study 28933971 — intervention group
Group type: COMPARATOR
Intervention: Fp DPI 500 mcg (250 mcg × 2 inhalations)
Number of subjects: 40
Study 28933971 — intervention group
Group type: COMPARATOR
Intervention: FS DPI 500/50 mcg
Number of subjects: 40
Study 28934175 — intervention group
Group type: EXPERIMENTAL
Intervention: Body Adiposity Index (BAI)
Number of subjects: 96
Study 28934175 — intervention group
Group type: COMPARATOR
Intervention: Bioelectrical Impedance Analysis (BIA)
Number of subjects: 96
Study 28934680 — intervention group
Group type: EXPERIMENTAL
Intervention: Gandotinib (LY2784544), a potent inhibitor of JAK2 activity
Number of subjects: 0
Study 28934789 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic WAD patients
Number of subjects: 52
Study 28934789 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 52
Study 28934932 — intervention group
Group type: EXPERIMENTAL
Intervention: Early KP group (≤3 years duration)
Number of subjects: 400
Study 28934932 — intervention group
Group type: EXPERIMENTAL
Intervention: Established KP group (>3 years)
Number of subjects: 400
Study 28934932 — intervention group
Group type: EXPERIMENTAL
Intervention: No KP group
Number of subjects: 400
Study 28934932 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline data
Number of subjects: 400
Study 28934932 — intervention group
Group type: EXPERIMENTAL
Intervention: Subsequent prospective data (Year 1 and Year 3)
Number of subjects: 400
Study 28935032 — intervention group
Group type: EXPERIMENTAL
Intervention: T2MI definition requiring the presence of coronary artery disease
Number of subjects: 4015
Study 28935032 — intervention group
Group type: COMPARATOR
Intervention: T2MI definition without requiring coronary artery disease
Number of subjects: 4015
Study 28935432 — intervention group
Group type: EXPERIMENTAL
Intervention: ravidasvir 200 mg QD plus sofosbuvir 400 mg QD for 12 weeks (with or without ribavirin)
Number of subjects: 298
Study 28935432 — intervention group
Group type: EXPERIMENTAL
Intervention: ravidasvir plus sofosbuvir with ribavirin for 12 or 16 weeks
Number of subjects: 298
Study 28935451 — intervention group
Group type: EXPERIMENTAL
Intervention: Ideal group (BCLC stage 0-A)
Number of subjects: 65
Study 28935451 — intervention group
Group type: COMPARATOR
Intervention: Nonideal group (BCLC stage beyond A)
Number of subjects: 65
Study 28935452 — intervention group
Group type: EXPERIMENTAL
Intervention: 3D image-guidance system (Explorer)
Number of subjects: 50
Study 28935452 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative chemotherapy (median 4 months, range 2-24 months)
Number of subjects: 50
Study 28935620 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-month physical activity track
Number of subjects: 71
Study 28935620 — intervention group
Group type: COMPARATOR
Intervention: 3-month dietary track
Number of subjects: 71
Study 28935620 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall satisfaction with ALIVE
Number of subjects: 71
Study 28935628 — intervention group
Group type: EXPERIMENTAL
Intervention: High-Intensity Interval Training (HIIT)
Number of subjects: 0
Study 28935628 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 28935629 — intervention group
Group type: EXPERIMENTAL
Intervention: Lyon Advance Care Planning Survey - Adolescent Version
Number of subjects: 96
Study 28935629 — intervention group
Group type: EXPERIMENTAL
Intervention: Lyon Advance Care Planning Survey - Surrogate Version
Number of subjects: 96
Study 28935718 — intervention group
Group type: EXPERIMENTAL
Intervention: Cooling therapy (prematurely discontinued)
Number of subjects: 10
Study 28935847 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention not specified
Number of subjects: 0
Study 28935847 — intervention group
Group type: COMPARATOR
Intervention: Control not specified
Number of subjects: 0
Study 28936121 — intervention group
Group type: EXPERIMENTAL
Intervention: Education intervention consisting of a two-day seminar and monthly coaching sessions for six months.
Number of subjects: 24
Study 28936121 — intervention group
Group type: EXPERIMENTAL
Intervention: Qualitative data collection through ethnographic fieldwork, qualitative interviews, and analysis of reflection notes.
Number of subjects: 24
Study 28936175 — intervention group
Group type: EXPERIMENTAL
Intervention: Lisdexamfetamine
Number of subjects: 0
Study 28936175 — intervention group
Group type: COMPARATOR
Intervention: D-Amphetamine
Number of subjects: 0
Study 28936597 — intervention group
Group type: COMPARATOR
Intervention: Immediate extubation
Number of subjects: 248
Study 28936597 — intervention group
Group type: EXPERIMENTAL
Intervention: Terminal weaning
Number of subjects: 248
Study 28936602 — intervention group
Group type: EXPERIMENTAL
Intervention: Mom Power (MP) Intervention
Number of subjects: 75
Study 28936602 — intervention group
Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 75
Study 28936626 — intervention group
Group type: EXPERIMENTAL
Intervention: Frailty (values ≥ 5)
Number of subjects: 5021
Study 28936626 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall ICU mortality
Number of subjects: 5021
Study 28936626 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall 30-day mortality
Number of subjects: 5021
Study 28936626 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients not receiving specific ICU procedures (ventilation, vasoactive drugs, renal replacement therapy)
Number of subjects: 5021
Study 28936626 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical Frailty Scale
Number of subjects: 5021
Study 28936952 — intervention group
Group type: EXPERIMENTAL
Intervention: Injection test with esophageal balloon catheter
Number of subjects: 20
Study 28937974 — intervention group
Group type: EXPERIMENTAL
Intervention: Somatic mutation burden
Number of subjects: 664
Study 28937974 — intervention group
Group type: EXPERIMENTAL
Intervention: Missense mutation load
Number of subjects: 664
Study 28937974 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoantigen burden
Number of subjects: 664
Study 28938419 — intervention group
Group type: EXPERIMENTAL
Intervention: FMV urinary LH
Number of subjects: 868
Study 28938419 — intervention group
Group type: EXPERIMENTAL
Intervention: Urinary LH
Number of subjects: 868
Study 28938419 — intervention group
Group type: EXPERIMENTAL
Intervention: Urinary LH (cut-off SD score of 2)
Number of subjects: 868
Study 28938419 — intervention group
Group type: EXPERIMENTAL
Intervention: Urinary concentrations of LH after 3 months of GnRH treatment
Number of subjects: 868
Study 28938424 — intervention group
Group type: EXPERIMENTAL
Intervention: Adiponectin
Number of subjects: 683
Study 28938424 — intervention group
Group type: EXPERIMENTAL
Intervention: Cholesterol efflux capacity (CEC)
Number of subjects: 683
Study 28938424 — intervention group
Group type: EXPERIMENTAL
Intervention: Age-stratified linear regression analyses
Number of subjects: 683
Study 28938429 — intervention group
Group type: EXPERIMENTAL
Intervention: Preconception impaired glucose tolerance (IGT)
Number of subjects: 1508
Study 28938478 — intervention group
Group type: EXPERIMENTAL
Intervention: Roux-en-Y gastric bypass (RYGB)
Number of subjects: 28
Study 28938478 — intervention group
Group type: COMPARATOR
Intervention: Laparoscopic adjustable gastric banding (LAGB)
Number of subjects: 28
Study 28938478 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucose-insulin infusion
Number of subjects: 28
Study 28938891 — intervention group
Group type: EXPERIMENTAL
Intervention: Culture-expanded, autologous, bone marrow-derived MSCs
Number of subjects: 33
Study 28938918 — intervention group
Group type: EXPERIMENTAL
Intervention: Stereotactic body radiotherapy (SBRT) at dose level 3 (36 Gy/3)
Number of subjects: 13
Study 28938918 — intervention group
Group type: EXPERIMENTAL
Intervention: Stereotactic body radiotherapy (SBRT) in combination with pazopanib
Number of subjects: 13
Study 28939374 — intervention group
Group type: EXPERIMENTAL
Intervention: Mesalazine
Number of subjects: 428
Study 28939374 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral corticosteroids
Number of subjects: 428
Study 28939374 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous corticosteroids
Number of subjects: 428
Study 28939487 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma Hsp90α measurement
Number of subjects: 1647
Study 28939546 — intervention group
Group type: EXPERIMENTAL
Intervention: Smart technology intervention (daily measurements with smartphone-compatible ECG device, BP monitor, weight scale, activity tracker; two electronic visits)
Number of subjects: 0
Study 28939546 — intervention group
Group type: EXPERIMENTAL
Intervention: Smart technology intervention
Number of subjects: 0
Study 28939546 — intervention group
Group type: COMPARATOR
Intervention: Regular care (four outpatient clinic visits)
Number of subjects: 0
Study 28939558 — intervention group
Group type: EXPERIMENTAL
Intervention: BVD-523 (ulixertinib), a novel, reversible, ATP-competitive ERK1/2 inhibitor
Number of subjects: 0
Study 28939558 — intervention group
Group type: EXPERIMENTAL
Intervention: BVD-523 (ulixertinib)
Number of subjects: 0
Study 28939558 — intervention group
Group type: COMPARATOR
Intervention: BRAF and MEK-targeted combination therapy
Number of subjects: 0
Study 28939688 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiorespiratory Fitness (CRF)
Number of subjects: 0
Study 28939688 — intervention group
Group type: COMPARATOR
Intervention: BMI categories
Number of subjects: 0
Study 28940225 — intervention group
Group type: EXPERIMENTAL
Intervention: Automated low-flow ascites pump (alfapump)
Number of subjects: 56
Study 28940435 — intervention group
Group type: EXPERIMENTAL
Intervention: Counselor MI inconsistent language
Number of subjects: 40
Study 28940435 — intervention group
Group type: EXPERIMENTAL
Intervention: Sustain talk
Number of subjects: 40
Study 28940435 — intervention group
Group type: EXPERIMENTAL
Intervention: MI inconsistent language (MIIN)
Number of subjects: 40
Study 28940435 — intervention group
Group type: EXPERIMENTAL
Intervention: Sustain talk early in the session (deciles 1 and 2)
Number of subjects: 40
Study 28940455 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient risk model
Number of subjects: 715
Study 28940455 — intervention group
Group type: EXPERIMENTAL
Intervention: Nodule risk model
Number of subjects: 715
Study 28940629 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol use (1 drink)
Number of subjects: 73
Study 28940629 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol use (2 nights later)
Number of subjects: 73
Study 28940629 — intervention group
Group type: EXPERIMENTAL
Intervention: Heavier drinking (4-5 drinks)
Number of subjects: 73
Study 28940629 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol use
Number of subjects: 73
Study 28940629 — intervention group
Group type: EXPERIMENTAL
Intervention: Insomnia symptoms
Number of subjects: 73
Study 28940967 — intervention group
Group type: EXPERIMENTAL
Intervention: 4-year MVPA
Number of subjects: 553
Study 28940967 — intervention group
Group type: EXPERIMENTAL
Intervention: 1-year MVPA
Number of subjects: 553
Study 28940967 — intervention group
Group type: COMPARATOR
Intervention: MVPA at year 1 (WL maintainers vs nonmaintainers)
Number of subjects: 553
Study 28940967 — intervention group
Group type: COMPARATOR
Intervention: MVPA at year 4 (WL maintainers vs nonmaintainers)
Number of subjects: 553
Study 28940967 — intervention group
Group type: EXPERIMENTAL
Intervention: Engagement in ≥250 min/wk of MVPA
Number of subjects: 553
Study 28940967 — intervention group
Group type: EXPERIMENTAL
Intervention: Engagement in <150 min/wk of MVPA
Number of subjects: 553
Study 28941023 — intervention group
Group type: EXPERIMENTAL
Intervention: Daclatasvir-based regimens
Number of subjects: 1503
Study 28941030 — intervention group
Group type: EXPERIMENTAL
Intervention: Brachytherapy
Number of subjects: 391
Study 28941030 — intervention group
Group type: COMPARATOR
Intervention: Bilateral nerve-sparing robot-assisted radical prostatectomy (RARP)
Number of subjects: 391
Study 28941036 — intervention group
Group type: EXPERIMENTAL
Intervention: Donor SUMO4 rs237025 AA carriers
Number of subjects: 297
Study 28941036 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined donor CYP3A5 rs776746 and donor SUMO4 rs237025 genotypes
Number of subjects: 297
Study 28941036 — intervention group
Group type: EXPERIMENTAL
Intervention: CYP3A5 mRNA expression in liver tissues
Number of subjects: 297
Study 28941036 — intervention group
Group type: EXPERIMENTAL
Intervention: SUMO4 rs237025 G allele
Number of subjects: 297
Study 28941036 — intervention group
Group type: EXPERIMENTAL
Intervention: Activation of NF-kB
Number of subjects: 297
Study 28941136 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic sinus surgery (ESS) for unilateral CRSsNP
Number of subjects: 190
Study 28941136 — intervention group
Group type: COMPARATOR
Intervention: Endoscopic sinus surgery (ESS) for bilateral CRSsNP
Number of subjects: 190
Study 28941219 — intervention group
Group type: EXPERIMENTAL
Intervention: Tofacitinib (1-30 mg twice daily or 20 mg once daily)
Number of subjects: 6194
Study 28941330 — intervention group
Group type: EXPERIMENTAL
Intervention: Islet preparations with a mean purity <50% (LOW purity)
Number of subjects: 24
Study 28941330 — intervention group
Group type: COMPARATOR
Intervention: Islet preparations with a mean purity ≥50% (HIGH purity)
Number of subjects: 24
Study 28941330 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-IT blood levels of CA 19-9 and glucagon
Number of subjects: 24
Study 28941620 — intervention group
Group type: EXPERIMENTAL
Intervention: ChAd63-MVA ME-TRAP with 25μg Matrix-M (n=8)
Number of subjects: 22
Study 28941620 — intervention group
Group type: EXPERIMENTAL
Intervention: ChAd63-MVA ME-TRAP with 50μg Matrix-M (n=8)
Number of subjects: 22
Study 28941620 — intervention group
Group type: COMPARATOR
Intervention: ChAd63-MVA ME-TRAP alone (n=6)
Number of subjects: 22
Study 28941623 — intervention group
Group type: EXPERIMENTAL
Intervention: MenACWY-D vaccine
Number of subjects: 31561
Study 28943010 — intervention group
Group type: EXPERIMENTAL
Intervention: Aorfix endograft
Number of subjects: 205
Study 28943010 — intervention group
Group type: EXPERIMENTAL
Intervention: Proximal neck diameter
Number of subjects: 205
Study 28943010 — intervention group
Group type: EXPERIMENTAL
Intervention: Seal zone inner curve length
Number of subjects: 205
Study 28943010 — intervention group
Group type: EXPERIMENTAL
Intervention: Neck diameter stratification
Number of subjects: 205
Study 28943279 — intervention group
Group type: EXPERIMENTAL
Intervention: Upper lobe-predominant emphysema (n=905)
Number of subjects: 9210
Study 28943279 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower lobe-predominant emphysema (n=796)
Number of subjects: 9210
Study 28943279 — intervention group
Group type: EXPERIMENTAL
Intervention: Minimal emphysema (n=1,312)
Number of subjects: 9210
Study 28943493 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravascular Ultrasound (IVUS) performed in a non-culprit coronary artery
Number of subjects: 846
Study 28943493 — intervention group
Group type: EXPERIMENTAL
Intervention: Genome-wide association study of plaque morphology
Number of subjects: 846
Study 28943515 — intervention group
Group type: EXPERIMENTAL
Intervention: Bleeding impacting mortality after noncardiac surgery (BIMS)
Number of subjects: 16079
Study 28943515 — intervention group
Group type: EXPERIMENTAL
Intervention: Diagnostic criteria for BIMS
Number of subjects: 16079
Study 28943515 — intervention group
Group type: EXPERIMENTAL
Intervention: Incidence of BIMS
Number of subjects: 16079
Study 28943515 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical prediction guide for BIMS
Number of subjects: 16079
Study 28943516 — intervention group
Group type: EXPERIMENTAL
Intervention: Mechanical thrombectomy (MT)
Number of subjects: 984
Study 28943894 — intervention group
Group type: EXPERIMENTAL
Intervention: Syndrome Z in obese women with MetS
Number of subjects: 83
Study 28944067 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic intervention (two daily tablets totalling 1.4×10)
Number of subjects: 15
Study 28944067 — intervention group
Group type: COMPARATOR
Intervention: Control group (patients without neoplastic or inflammatory disease)
Number of subjects: 15
Study 28944597 — intervention group
Group type: EXPERIMENTAL
Intervention: Very Low-Calorie Diet (VLCD)
Number of subjects: 15
Study 28944613 — intervention group
Group type: EXPERIMENTAL
Intervention: PF-SES
Number of subjects: 0
Study 28944613 — intervention group
Group type: COMPARATOR
Intervention: BMS
Number of subjects: 0
Study 28944714 — intervention group
Group type: EXPERIMENTAL
Intervention: Gymnemic acids (GA) lozenge
Number of subjects: 67
Study 28944714 — intervention group
Group type: COMPARATOR
Intervention: Placebo lozenge
Number of subjects: 67
Study 28945120 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate
Number of subjects: 60
Study 28945120 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 28945476 — intervention group
Group type: EXPERIMENTAL
Intervention: Lungs recovered from uDCDDs
Number of subjects: 502
Study 28945476 — intervention group
Group type: EXPERIMENTAL
Intervention: Lungs assessed by 4 hours ex vivo lung perfusion (EVLP)
Number of subjects: 502
Study 28945476 — intervention group
Group type: COMPARATOR
Intervention: Lungs from brain-dead donors (control group)
Number of subjects: 502
Study 28945839 — intervention group
Group type: EXPERIMENTAL
Intervention: GRANT score (based on Fuhrman grade, age, pathological nodal status, and pathological tumor size)
Number of subjects: 0
Study 28945839 — intervention group
Group type: COMPARATOR
Intervention: Already validated score systems
Number of subjects: 0
Study 28945848 — intervention group
Group type: EXPERIMENTAL
Intervention: Panitumumab in combination with irinotecan
Number of subjects: 39
Study 28945848 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma testing of cell-free DNA by BEAMing
Number of subjects: 39
Study 28945848 — intervention group
Group type: EXPERIMENTAL
Intervention: Emergent RAS mutations at progression
Number of subjects: 39
Study 28945848 — intervention group
Group type: EXPERIMENTAL
Intervention: Serial analysis of plasma samples
Number of subjects: 39
Study 28945884 — intervention group
Group type: EXPERIMENTAL
Intervention: Lenalidomide plus rituximab
Number of subjects: 66
Study 28945911 — intervention group
Group type: EXPERIMENTAL
Intervention: E/C/F/TDF therapy, no LXR agonist
Number of subjects: 10
Study 28945911 — intervention group
Group type: EXPERIMENTAL
Intervention: E/C/F/TDF therapy, LXR agonist
Number of subjects: 10
Study 28945911 — intervention group
Group type: COMPARATOR
Intervention: Non-HIV-infected subjects, no LXR agonist
Number of subjects: 10
Study 28945911 — intervention group
Group type: COMPARATOR
Intervention: Non-HIV-infected subjects, LXR agonist
Number of subjects: 10
Study 28946849 — intervention group
Group type: EXPERIMENTAL
Intervention: S. aureus ICU acquired pneumonia
Number of subjects: 2000
Study 28946849 — intervention group
Group type: EXPERIMENTAL
Intervention: P. aeruginosa ICU acquired pneumonia
Number of subjects: 2000
Study 28946874 — intervention group
Group type: EXPERIMENTAL
Intervention: Periurethral injection of autologous regenerative cells from adipose tissue using the Celution® system
Number of subjects: 45
Study 28947018 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood eosinophilia ≥2%
Number of subjects: 207
Study 28947018 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood eosinophilia ≥300 cell/microliter
Number of subjects: 207
Study 28947018 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood eosinophilia <2%
Number of subjects: 207
Study 28947018 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood eosinophilia ≥2% and ≥300 cell/microliter
Number of subjects: 207
Study 28947346 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 Pillars™ Practice Transformation Program
Number of subjects: 9473
Study 28947452 — intervention group
Group type: EXPERIMENTAL
Intervention: Various imaging modalities for the assessment of hand OA
Number of subjects: 300